Federal RuleAug 21
62
DOL Rewrites Disability Rules for 'Merit-Based Opportunity' Push
RuleLabor DepartmentFederal Contract Compliance Programs OfficeSignificant Wallet
HR7879119th CongressWALLET
SUPER BUGS Act of 2026
Sponsored By: Representative Levin, Mike [D-CA-49]
Introduced
Summary
A coordinated international strategy to develop and commercialize pandemic medical products would direct the Secretary of State, working with HHS and other agencies, to build a global plan within 18 months to secure support for qualified pandemic or epidemic products, including tools against antimicrobial resistant pathogens.
Show full summary
- Families and patients would see a focus on faster development and commercialization of vaccines, treatments, and diagnostics for pandemic threats and antibiotic resistant pathogens. The strategy would identify priority actions to steer scarce funds to the highest impact products.
- Partner countries and global health systems would get support to strengthen detection, prevention, and containment. The plan would promote equitable contributions, harmonize efforts to avoid duplication, and set up arrangements with foreign governments and multilateral organizations.
- U.S. companies and the private sector would be considered in contracts and public private partnerships. The strategy would explore alternative payment models, coverage and reimbursement pathways, and streamlined regulatory coordination to help commercialize qualifying products.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Global plan for pandemic products
If enacted, the bill would require the Secretary of State, with HHS and other agencies, to write a federal strategy within 18 months. The strategy would seek international support to develop and commercialize qualified pandemic or epidemic products, including products for antimicrobial-resistant and other priority pathogens. It would require processes for entering international arrangements, harmonizing new and existing efforts, strengthening partner-country public-health capacity, and identifying funding priorities. The strategy would have to consider contracts with U.S. companies, public-private partnerships, alternative payment and coverage approaches, faster regulatory pathways, and be submitted to four congressional committees.
Sponsors & CoSponsors
Sponsor
Levin, Mike [D-CA-49]
CA • D
Cosponsors
Rep. Valadao, David G. [R-CA-22]
CA • R
Sponsored 3/9/2026
Rep. Fitzpatrick, Brian K. [R-PA-1]
PA • R
Sponsored 3/19/2026
Rep. Costa, Jim [D-CA-21]
CA • D
Sponsored 4/30/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov